A couple of novel epitopes have been identified, for example, EGFR variant III (EGFRvIII) is a tumor-specific protein present in 25–30% of newly diagnosed glioblastomas (GBMs), making it a potential option for CAR T-cell therapy [161]. Here, EGFR is linked to neoplasm.